PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.14%
Revenue growth under 50% of META's 19.58%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
6.04%
Gross profit growth under 50% of META's 21.48%. Michael Burry would be concerned about a severe competitive disadvantage.
11.72%
EBIT growth below 50% of META's 36.02%. Michael Burry would suspect deeper competitive or cost structure issues.
11.72%
Operating income growth under 50% of META's 36.02%. Michael Burry would be concerned about deeper cost or sales issues.
15.93%
Net income growth at 50-75% of META's 31.41%. Martin Whitman would question fundamental disadvantages in expenses or demand.
16.13%
EPS growth under 50% of META's 35.85%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
16.67%
Diluted EPS growth under 50% of META's 36.54%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.22%
Share reduction while META is at 0.59%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.35%
Reduced diluted shares while META is at 0.55%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
19.09%
OCF growth above 1.5x META's 7.21%. David Dodd would confirm a clear edge in underlying cash generation.
33.79%
FCF growth above 1.5x META's 19.02%. David Dodd would verify if the firm’s strategic investments yield superior returns.
670.09%
10Y revenue/share CAGR 1.25-1.5x META's 506.49%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
123.80%
5Y revenue/share CAGR under 50% of META's 506.49%. Michael Burry would suspect a significant competitive gap or product weakness.
47.77%
3Y revenue/share CAGR under 50% of META's 203.17%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
854.43%
10Y OCF/share CAGR under 50% of META's 1990.83%. Michael Burry would worry about a persistent underperformance in cash creation.
143.49%
Below 50% of META's 1990.83%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
87.91%
3Y OCF/share CAGR at 75-90% of META's 106.60%. Bill Ackman would press for improvements in margin or overhead to catch up.
494.98%
Net income/share CAGR at 50-75% of META's 699.82%. Martin Whitman might question if the firm’s product or cost base lags behind.
82.92%
Below 50% of META's 699.82%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
46.46%
Below 50% of META's 487.24%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
742.21%
Equity/share CAGR of 742.21% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
131.09%
Equity/share CAGR of 131.09% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
57.22%
Below 50% of META's 248.44%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
17.97%
AR growth well above META's 19.29%. Michael Burry fears inflated revenue or higher default risk in the near future.
-100.00%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.04%
Asset growth well under 50% of META's 7.04%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.71%
50-75% of META's 6.23%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-19.30%
We’re deleveraging while META stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-0.12%
Our R&D shrinks while META invests at 8.94%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.56%
SG&A declining or stable vs. META's 9.98%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.